Proton Therapy Partnerships Leo Cancer Care is advancing a compact proton therapy delivery model through a collaboration with Mevion Medical Systems and a demonstrated integration at Stanford Medicine. This creates a sales opportunity with proton therapy centers seeking patient friendly upright positioning, reduced infrastructure requirements, and streamlined imaging workflows.

Regulatory Milestones Key products are not yet commercially available as the company is pursuing FDA approval and CE marking. This points to opportunities to engage early adopter research hospitals for pilots or trials, and to position the company as a partner for regulatory navigation, installation and training.

Market Expansion Signals Recent European showcases at ESTRO and plans to bring Grace to Europe indicate a path for geographic expansion. Partnerships with Orfit and the Mevion Stanford collaboration provide multi network routes to scale, suggesting targets among cancer centers upgrading radiotherapy infrastructure in Europe and North America.

Patient Experience Focus Upright positioning is framed as improving patient experience and access, a compelling differentiator for centers focused on patient-centric care and throughput. Potential to bundle imaging and QA components including Terapet QUALYSCAN and Orfit immobilization to create a full workflow solution.

Integrated Solution Stack Leo's Marie upright positioning and imaging system along with the Grace upright photon therapy concept and the ongoing integrations with Mevion and Terapet create an integrated solution stack. The opportunity is to approach cancer centers seeking end to end upright treatment options and to partner with proton and imaging QA vendors to offer a modular, scalable platform.